Navigation Links
Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies
Date:11/6/2007

LINCOLN, R.I., Nov. 6 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today the completion of enrollment of three on-going clinical studies. Each study is evaluating NT-501, the Company's lead product, for the treatment of visual loss associated with retinitis pigmentosa (RP) and the dry form of age-related macular degeneration (dry AMD). NT-501 is an intraocular, cell containing polymer implant designed to provide the continuous, long-term release of the therapeutic protein, Ciliary Neurotrophic Factor (CNTF), directly into the back of the eye by means of the Company's proprietary Encapsulated Cell Technology (ECT).

"This is a very significant achievement for the Company and a critical milestone in the development of NT-501," said Ted Danse, President and CEO of Neurotech. "We are very pleased with how quickly enrollment was completed for all three clinical studies and we anticipate announcing top line results for these studies by the end of FY 2008."

"The Foundation Fighting Blindness has been a key partner in both the preclinical and clinical studies of the NT-501," said Stephen Rose, Ph.D., Chief Research Officer of the Foundation. "We are particularly excited about Neurotech's treatment, because it holds promise for saving the vision of people affected by a range of retinal degenerative diseases."

RP is an inherited disease that causes the retina's rod and cone photoreceptors to gradually degenerate leading to loss of vision and blindness. The symptoms of RP predominately appear in young adults and affect approximately 100,000 people in the United States and over 1 million people worldwide. At this time there is no known cure or effective treatment for RP.

AMD is a chronic progressive disease of the macula that results in the loss of central vision. It is the leading cause of blindness in elderly people in the developed world. There are two forms of AMD; dry and wet. Dry AMD is the most common form of AMD representing approximately 90% of all AMD cases. In its later stages dry AMD involves the degeneration of photoreceptors and retinal pigment epithelial cells, a chronic condition called geographic atrophy (GA). GA affects approximately 1 million people in the United States for which there currently are no effective treatments.

Phase II/III Study - RP (early stage)

This randomized, multi-centered, double-masked, sham controlled study is evaluating NT-501 in 60 subjects with early stage RP. Each subject receives either a high or low dose NT-501 implant in one eye and a sham treatment in the other eye. Visual field sensitivity is the primary efficacy endpoint of this study.

Phase II/III Study - RP (late stage)

This randomized, multi-centered, double-masked, sham controlled study is evaluating NT-501 in 60 subjects with late stage RP. Each subject receives either a high or low dose NT-501 implant in one eye and a sham treatment in the other eye. Visual acuity is the primary efficacy endpoint of this study.

Phase II Study - dry AMD

This randomized, multi-centered, double-masked, sham controlled study is evaluating NT-501 in 48 subjects with dry AMD. Each subject receives either a high or low dose NT-501 implant or a sham treatment in one eye only. Visual acuity is the primary efficacy endpoint of this study.

About Neurotech

Neurotech is a privately-held biotechnology company located in Lincoln, Rhode Island, specializing in the development of sight-saving therapeutics for chronic retinal diseases. Retinal diseases represent significant unmet medical needs for which new medical therapies are the largest market opportunity in ophthalmology.

Neurotech's lead product (NT-501) is in two Phase II/III clinical trials for the treatment of visual loss associated with retinitis pigmentosa and a Phase II trial for the treatment of the dry form of age-related macular degeneration. Neurotech is also evaluating other factors that can be used with its proprietary delivery technology, Encapsulated Cell Technology (ECT), to treat additional retinal diseases.

To learn more about Neurotech and the clinical studies of NT-501, please visit our web site at http://www.neurotechusa.com.


'/>"/>
SOURCE Neurotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Neurotechnology Industry Organization Unveils Top 10 Neuroscience Trends of 2007
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology: